Shanghai Refreshgene Technology Co., Ltd.
1 clinical trials · Sponsor
◉ Watch Shanghai Refreshgene Technology Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) (NCT06141460) | Shanghai Refreshgene Technology Co., Ltd. | 2023-12-12 |
Track Shanghai Refreshgene Technology Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.